Bedrijf laden
Just reported
Q3 2026 results
From Arbutus Biopharma's results release of 10 november 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 299K
-43% y/y
-71% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$ 0,30
Guided
—
No guide given
Operating income, GAAP
Actual
US$ -10,5M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Arbutus Biopharma is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.US$ 48BA+
EXELExelixis, Inc.US$ 17,3BA+
JAZZJazz Pharmaceuticals plcUS$ 15,9BA
HALOHalozyme Therapeutics, Inc.US$ 11,6BA+
TECHBIO-Techne CorpUS$ 11,4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 okt 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 okt 2026BAGraded B, now A
Gebouwd uit de eigen deponeringen van Arbutus Biopharma Corp. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
